Ascletis Pharma Inc. (1672) presented multiple updates at ObesityWeek® 2025 in Atlanta, Georgia, highlighting new clinical data for ASC30 in both oral and subcutaneous injection forms, as well as preclinical results for a combination of ASC31 and ASC47.

Positive findings from the Phase Ib study of once-daily ASC30 oral tablets showed a placebo-adjusted mean body weight reduction of up to 6.5% after 28 days, with the highest dose group demonstrating up to 9.3% reduction. The safety profile included only mild-to-moderate gastrointestinal events without any severe adverse events.

The Phase Ib data for ASC30 subcutaneous injections revealed observed half-lives of 46 days and 75 days for two distinct formulations, supporting once-monthly and once-quarterly dosing regimens. Both formulations were reported as safe and well tolerated, with mild-to-moderate treatment-emergent events and no severe cases.

Preclinical studies combining ASC31—an investigational dual GLP-1 and GIP receptor peptide agonist—and the thyroid hormone receptor beta agonist ASC47 demonstrated marked superiority over tirzepatide and ASC31 monotherapy in reducing weight and body fat in mouse models of diet-induced obesity. The combination approached the body composition of healthy non-obese mice while preserving muscle mass.

According to the announcement, these results showcase the breadth of Ascletis Pharma’s obesity pipeline, supported by its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery and Ultra-Long-Acting platforms.